Fresenius Medical Care delivered strong Q4 2025 results and improved meaningfully in FY2025 versus FY2024. But with reimbursement tailwinds fading and new investments rising, 2026 looks like a transition year.

My stock analysis for LSEG (London Stock Exchange Group) — a global financial infrastructure and data platform with recurring revenue from analytics, index licensing, and post-trade services. This investment thesis explains its economic moat, key risks, ROIC considerations, and why it fits a long-term, quality-compounding strategy.

Fresenius Medical Care AG's share price has declined in Jan 2026, raising questions for long-term investors. This analysis reviews FMS’s fundamentals.

I turned a Xiaomi stock investment into a 104.3% return with a 15.6% CAGR. Here’s how I doubled my investment by sticking to my thesis, reviewing regularly, and holding through volatility — even when the stock was down 50%.